<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pentostatin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pentostatin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pentostatin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11408" href="/d/html/11408.html" rel="external">see "Pentostatin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709202"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pentostatin should be administered under the supervision of a physician qualified and experienced in the use of cancer chemotherapeutic agents. </p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Drug toxicities: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of higher doses than those specified is not recommended. Dose-limiting severe renal, liver, pulmonary, and CNS toxicities occurred in Phase 1 studies that used pentostatin at higher doses (20 to 50 mg/m2 in divided doses over 5 days) than recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">In a clinical investigation in patients with refractory chronic lymphocytic leukemia using pentostatin at the recommended dose in combination with fludarabine phosphate, 4 of 6 patients entered in the study had severe or fatal pulmonary toxicity. The use of pentostatin in combination with fludarabine phosphate is not recommended.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F182953"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nipent</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F182981"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antimetabolite;</li>
<li>
                        Antineoplastic Agent, Antimetabolite (Purine Analog)</li></ul></div>
<div class="block doa drugH1Div" id="F182956"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c2daff1-da41-460d-97f5-616d486189ba">Chronic lymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Previously treated:</i>
<b> IV:</b> 4 mg/m<sup>2</sup> once every 3 weeks (in combination with cyclophosphamide and rituximab) for 6 cycles (Lamanna 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Previously untreated:</i>
<b>IV: </b>2 mg/m<sup>2</sup> once every 3 weeks (in combination with cyclophosphamide and rituximab) for 6 cycles (Kay 2007).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="650686bd-b083-4b8a-872a-157a5165c1b2">Cutaneous T-cell lymphoma, mycosis fungoides/Sezary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous T-cell lymphoma, mycosis fungoides/Sezary syndrome (off-label use):</b>
<b>IV:</b> 4 mg/m<sup>2</sup> once weekly for 3 weeks, then 4 mg/m<sup>2 </sup>once every 2 weeks for 6 weeks, then 4 mg/m<sup>2</sup> once a month for a maximum of 6 months (Ho 1999).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee83bdbc-6f57-438d-9ad5-ce26b1ad18ef">Graft-versus-host disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute graft-versus-host disease, steroid-refractory:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial therapy: <b>IV: </b>1.5 mg/m<sup>2</sup> days 1 to 3 and days 15 to 17 (in combination with corticosteroids) (Alousi 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">Steroid-refractory disease: <b>IV: </b>1.5 mg/m<sup>2</sup> daily for 3 days; may repeat after 2 weeks if needed (Bolanos-Meade 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic graft-versus-host disease, steroid-refractory:</b>
<b>IV:</b> 4 mg/m<sup>2</sup> once every 2 weeks; discontinue after 6 months for sustained objective response, or continue every 2 to 4 weeks for up to 12 months if still improving (Jacobsohn 2007; Jacobsohn 2009) <b>or</b> 4 mg/m<sup>2</sup> once every 2 weeks for 3 months (Wolff 2011).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6809a202-6933-4fe2-a689-981abd6e2a63">Hairy cell leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hairy cell leukemia (previously untreated or refractory):</b>
<b>IV:</b> 4 mg/m<sup>2</sup> once every 2 weeks. <b>Note:</b> The optimal duration has not been determined; in the absence of unacceptable toxicity, may continue until complete response is achieved or until 2 doses after complete response. Discontinue after 12 months if the best response achieved is a partial response or after 6 months if partial or complete response is not achieved. Consensus guidelines suggest pentostatin may be continued until hematologic parameters have normalized and splenomegaly is no longer present on physical exam (Grever 2017).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b612618d-fa2f-490f-a64e-3c2acb93b2e7">T-cell large granular lymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>T-cell large granular lymphocytic leukemia (off-label use; based on limited data): IV:</b> 4 mg/m<sup>2</sup> once every 1 to 2 weeks until maximum response is achieved (Osuji 2006) <b>or</b> 4 to 5 mg/m<sup>2</sup> every 2 weeks for 8 courses (Fortune 2010) <b>or</b> 4 mg/m<sup>2</sup> once a week (in combination with alemtuzumab) (Aribi 2007).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70171e62-ed4a-483b-910f-e5d1cbeb956a">T-cell prolymphocytic leukemia, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>T-cell prolymphocytic leukemia, refractory (off-label use): IV:</b> 4 mg/m<sup>2</sup> once weekly for 4 weeks, then 4 mg/m<sup>2</sup> every 2 weeks until optimum response is achieved (Mercieca 1994) <b>or</b> 4 mg/m<sup>2</sup> once weekly for 4 weeks, then 4 mg/m<sup>2</sup> every 2 weeks (in combination with alemtuzumab) until complete or best response or up to a total of 14 doses (Ravandi 2009).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990351"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; although not adequately studied, two patients with CrCl 50 to 60 mL/minute achieved responses when treated with 2 mg/m<sup>2</sup>/dose. For renal toxicity <i>during</i> treatment, withhold pentostatin for elevated serum creatinine and determine CrCl.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have also been recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Indication not specified (Kintzel 1995):</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 46 to 60 mL/minute: Administer 70% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 31 to 45 mL/minute: Administer 60% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Consider use of alternative drug.</p>
<p style="text-indent:-2em;margin-left:4em;">Indication not specified (Lathia 2002):</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥60 mL/minute: Administer 4 mg/m<sup>2</sup>/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 40 to 59 mL/minute: Administer 3 mg/m<sup>2</sup>/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 20 to 39 mL/minute: Administer 2 mg/m<sup>2</sup>/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Chronic lymphocytic leukemia, previously treated (off-label use; Lamanna 2006): Serum creatinine &gt;2 mg/dL or 20% above patient's baseline: Withhold treatment until serum creatinine ≤2 mg/dL or returns to baseline, or until CrCl ≥50 mL/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Graft-versus-host disease (off-label use; Alousi 2009; Bolanos-Meade 2005; Jacobsohn 2007; Jacobsohn 2009; Poi 2013; Wolff 2011):</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: Reduce dose by 50%.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Withhold dose.</p>
<p style="text-indent:-2em;margin-left:4em;">T-cell prolymphocytic leukemia, refractory (off-label use; Ravandi 2009):</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥60 mL/minute: Administer 4 mg/m<sup>2</sup>/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 40 to 59 mL/minute: Administer 3 mg/m<sup>2</sup>/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 35 to 39 mL/minute: Administer 2 mg/m<sup>2</sup>/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;35 mL/minute: Withhold treatment until CrCl ≥35 mL/minute.</p></div>
<div class="block doha drugH1Div" id="F50987723"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doo drugH1Div" id="F20343888"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2 </sup></i>
<i>(<b>Note:</b> Excludes hematopoietic cell transplantation dosing</i>
<i>):</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>American Society for Blood and Marrow Transplantation practice guideline committee position statement on chemotherapy dosing in obesity:</i> Utilize actual body weight (full weight) for calculation of BSA in pentostatin dosing for hematopoietic stem cell transplant conditioning regimens in adults (ASBMT [Bubalo 2014]).</p></div>
<div class="block dot drugH1Div" id="F26022907"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Acute graft-versus-host disease (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:4em;">ANC &lt;500/mm<sup>3</sup>: Withhold treatment until ANC recovery (Alousi 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">ANC 500 to &lt;1,000/mm<sup>3</sup>: Reduce dose by 50% (Alousi 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Chronic graft-versus-host disease (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:4em;">ANC &lt;500/mm<sup>3</sup>, platelets &lt;20,000/mm<sup>3</sup>, or neutropenic fever: Reduce dose by 50% (Jacobsohn 2007; Jacobsohn 2009; Wolff 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">ANC 500 to 1,000/mm<sup>3</sup>: Reduce dose by 25% (Jacobsohn 2007; Wolff 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hairy cell leukemia: </i></p>
<p style="text-indent:-2em;margin-left:4em;">ANC &lt;200/mm<sup>3</sup> (with baseline ANC &gt;500/mm<sup>3</sup>): Temporarily interrupt treatment until ANC returns to pre-dose levels.</p>
<p style="text-indent:-2em;margin-left:4em;">CNS toxicity: Withhold treatment or discontinue.</p>
<p style="text-indent:-2em;margin-left:4em;">Infection, active: Interrupt treatment until infection is controlled.</p>
<p style="text-indent:-2em;margin-left:4em;">Rash: Severe rashes may require treatment interruption or discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">Other severe adverse reactions: Withhold treatment or discontinue.</p></div>
<div class="block doe drugH1Div" id="F182957"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F182928"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (29% to 42%), pain (8% to 20%), chills (11% to 19%), headache (13% to 17%), central nervous system toxicity (1% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (26% to 43%), pruritus (10% to 21%), skin changes (4% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (≤63%), vomiting (≤63%), diarrhea (15% to 17%), anorexia (13% to 16%), abdominal pain (4% to 16%), stomatitis (5% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia (22% to 60%), anemia (8% to 35%), thrombocytopenia (6% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (2% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (7% to 38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (11% to 19%), asthenia (10% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (17% to 20%), upper respiratory tract infection (13% to 16%), rhinitis (10% to 11%), dyspnea (8% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (42% to 46%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (3% to 10%), facial edema (3% to 10%), hypotension (3% to 10%), peripheral edema (3% to 10%), angina pectoris (&lt;3%), atrioventricular block (&lt;3%), bradycardia (&lt;3%), cardiac arrhythmia (&lt;3%), cardiac failure (&lt;3%), deep vein thrombophlebitis (&lt;3%), hypertension (&lt;3%), pericardial effusion (&lt;3%), phlebitis (&lt;3%), pulmonary embolism (&lt;3%), sinoatrial arrest (&lt;3%), syncope (&lt;3%), tachycardia (&lt;3%), vasculitis (&lt;3%), ventricular premature contractions (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Anxiety (3% to 10%), confusion (3% to 10%), depression (3% to 10%), dizziness (3% to 10%), drowsiness (3% to 10%), insomnia (3% to 10%), nervousness (3% to 10%), paresthesia (3% to 10%), abnormal dreams (&lt;3%), abnormality in thinking (&lt;3%), amnesia (&lt;3%), ataxia (&lt;3%), dysarthria (&lt;3%), emotional lability (&lt;3%), encephalitis (&lt;3%), hallucination (&lt;3%), hangover effect (&lt;3%), hostility (&lt;3%), meningism (&lt;3%), neuralgia (&lt;3%), neuritis (&lt;3%), neuropathy (&lt;3%), neurosis (&lt;3%), paralysis (&lt;3%), seizure (&lt;3%), twitching (&lt;3%), vertigo (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (8% to 10%), urticaria (3% to 10%), xeroderma (3% to 10%), cellulitis (6%), furunculosis (4%), acne vulgaris (&lt;3%), alopecia (&lt;3%), eczema (&lt;3%), skin photosensitivity (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (&lt;3%), decreased libido (&lt;3%), hypercalcemia (&lt;3%), hyponatremia (&lt;3%), gout (&lt;3%), loss of libido (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (3% to 10%), flatulence (3% to 10%), gingivitis (3% to 10%), constipation (&lt;3%), dysgeusia (&lt;3%), dysphagia (&lt;3%), glossitis (&lt;3%), intestinal obstruction (&lt;3%), oral candidiasis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (3%), impotence (&lt;3%), lump in breast (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (3% to 10%), hemorrhage (3% to 10%), acute leukemia (&lt;3%), aplastic anemia (&lt;3%), hemolytic anemia (&lt;3%), neoplasm (&lt;3%), petechial rash (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (8%), viral infection (8%), bacterial infection (5%), herpes simplex infection (4%), sepsis (3%), abscess (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (3% to 6%), arthritis (&lt;3%), hyperkinetic muscle activity (&lt;3%), osteomyelitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (4%), amblyopia (&lt;3%), disease of the lacrimal apparatus (&lt;3%), nonreactive pupils (&lt;3%), photophobia (&lt;3%), retinopathy (&lt;3%), visual disturbance (&lt;3%), watery eyes (&lt;3%), xerophthalmia (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness (&lt;3%), labyrinthitis (&lt;3%), otalgia (&lt;3%), tinnitus (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (3% to 10%), nephrolithiasis (&lt;3%), renal disease (&lt;3%), renal failure syndrome (&lt;3%), renal function abnormality (&lt;3%), renal insufficiency (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (8% to 10%), sinusitis (6%), pneumonia (5%), asthma (3% to 10%), bronchitis (3%), bronchospasm (&lt;3%), flu-like symptoms (&lt;3%), laryngeal edema (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Fungal skin infection, uveitis, vision loss</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression, neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary toxicity</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Acute respiratory failure, autoimmune thrombocytopenia, exfoliative dermatitis, febrile neutropenia, hemolytic-uremic syndrome, pulmonary edema, thrombotic thrombocytopenic purpura</p></div>
<div class="block coi drugH1Div" id="F182941"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to pentostatin or any component of the formulation </p></div>
<div class="block war drugH1Div" id="F182925"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Myelosuppression may occur, primarily in the early treatment courses. Neutropenia may worsen during initial courses for the treatment of hairy cell leukemia. If severe neutropenia persists beyond early cycles, evaluate for disease status (including bone marrow examination). Monitor blood counts during treatment (more frequently in the initial cycles).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS toxicity: <b>[US Boxed Warning]: Severe CNS toxicities have occurred with doses higher than recommended; do not exceed the recommended dose. </b>Withhold treatment or discontinue for CNS toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Severe rashes may occur and may worsen with therapy continuation; may require treatment interruption or discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: <b>[US Boxed Warning]: Severe liver toxicities have occurred with doses higher than recommended; do not exceed the recommended dose. </b>May cause elevations (usually reversible) in liver function tests.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: <b>[US Boxed Warning]: <b>Severe pulmonary toxicities have occurred with doses higher than recommended; do not exceed the recommended dose. Concomitant use with fludarabine has resulted in serious or fatal pulmonary toxicity; the use of pentostatin in combination with fludarabine is not recommended. </b></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: <b>[US Boxed Warning]: Severe renal toxicities have occurred with doses higher than recommended; do not exceed the recommended dose.</b> Serum creatinine elevations occurring at recommended doses are usually minor and reversible. Withhold treatment for elevated serum creatinine and determine creatinine clearance. May require dosage adjustment or therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Preexisting infections may worsen with pentostatin treatment; if possible, infections should be resolved prior to pentostatin treatment initiation. Temporarily withhold pentostatin for active infection during therapy. Guidelines from the Hairy Cell Leukemia Society suggest that pentostatin has been used in patients with an active infection (Grever 2017). Use in patients with infections only if the potential benefit justifies the potential risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal dysfunction (CrCl &lt;60 mL/minute); the terminal half-life is prolonged; may require dosage adjustment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Drug-drug interactions: Concurrent use with fludarabine has resulted in severe or fatal pulmonary toxicity and is not recommended. Fatal pulmonary edema and hypotension have been reported in patients treated with pentostatin in combination with carmustine, etoposide, or high-dose cyclophosphamide as part of a myeloablative regimen for bone marrow transplant.</p></div>
<div class="block foc drugH1Div" id="F182935"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nipent: 10 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F182921"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323197"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Nipent Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $3,219.58</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F182938"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer IV over 20 to 30 minutes or as a bolus infusion. Hydrate with 500 to 1,000 mL fluid prior to infusion and 500 mL after infusion.</p></div>
<div class="block hazard drugH1Div" id="F49132755"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F182936"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hairy cell leukemia:</b> Treatment (as a single agent) of untreated and interferon alfa-refractory hairy cell leukemia in patients with active disease (clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms).</p></div>
<div class="block off-label drugH1Div" id="F25744620"><span class="drugH1">Use: Off-Label: Adult</span><p>Chronic lymphocytic leukemia; Cutaneous T-cell lymphomas, mycosis fungoides/Sezary syndrome; Graft-versus-host disease, acute (treatment); Graft-versus-host disease, chronic, steroid-refractory (treatment); T-cell large granular lymphocytic leukemia; T-cell prolymphocytic leukemia, refractory</p></div>
<div class="block mst drugH1Div" id="F182988"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pentostatin may be confused with pentamidine, pentosan</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nipent [US, Canada, and multiple international markets] may be confused with Nipin brand name for nifedipine [Italy, Singapore]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299851"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F182930"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fludarabine: Pentostatin may enhance the adverse/toxic effect of Fludarabine. Specifically, the risk of fatal pulmonary toxicity may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelarabine: Pentostatin may decrease serum concentrations of the active metabolite(s) of Nelarabine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegademase Bovine: May diminish the therapeutic effect of Pentostatin. Pentostatin may diminish the therapeutic effect of Pegademase Bovine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49320748"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Females of reproductive potential should avoid becoming pregnant during treatment.</p></div>
<div class="block pri drugH1Div" id="F182943"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and on findings from animal reproduction studies, in utero exposure to pentostatin may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F5517182"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if pentostatin is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made to discontinue pentostatin or breastfeeding, taking into account the importance of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F5517303"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential and platelet count (prior to each dose; more frequently during initial cycles), peripheral blood smears (periodically for hairy cells and to assess treatment response), liver function, serum uric acid, renal function (serum creatinine and/or CrCl at baseline, and serum creatinine prior to each dose), bone marrow evaluation. Monitor for signs/symptoms of pulmonary, CNS, and dermatologic toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F182924"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pentostatin is a purine antimetabolite that inhibits adenosine deaminase, preventing the deamination of adenosine to inosine. Accumulation of deoxyadenosine (dAdo) and deoxyadenosine 5′-triphosphate (dATP) results in a reduction of purine metabolism which blocks DNA synthesis and leads to cell death.</p></div>
<div class="block phk drugH1Div" id="F182940"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: IV: 20 L/m<sup>2</sup> (Lathia 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~4%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: 5.7 hours; Renal impairment (CrCl &lt;50 mL/minute): 18 hours (range: 11 to 23 hours [Lathia 2002]).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~90%).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: Adults: 68 mL/minute/m<sup>2</sup> (mean).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F182944"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Coforin | Coforin yamakawa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Nipent</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19443659">
<a name="19443659"></a>Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Blood</i>. 2009;114(3):511-517.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/19443659/pubmed" id="19443659" target="_blank">19443659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17045649">
<a name="17045649"></a>Aribi A, Huh Y, Keating M, et al. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. <i>Leuk Res.</i> 2007;31(7):939-945. doi: 10.1016/j.leukres.2006.09.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/17045649/pubmed" id="17045649" target="_blank">17045649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15837980">
<a name="15837980"></a>Bolanos-Meade J, Jacobsohn DA, Margolis J, et al, “Pentostatin in Steroid-Refractory Acute Graft-Versus-Host Disease,” <i>J Clin Oncol</i>, 2005, 23(12):2661-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/15837980/pubmed" id="15837980" target="_blank">15837980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24462742">
<a name="24462742"></a>Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616. doi: 10.1016/j.bbmt.2014.01.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/24462742/pubmed" id="24462742" target="_blank">24462742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20367569">
<a name="20367569"></a>Fortune AF, Kelly K, Sargent J, et al. Large granular lymphocyte leukemia: natural history and response to treatment. <i>Leuk Lymphoma.</i> 2010;51(5):839-845. doi: 10.3109/10428191003706947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/20367569/pubmed" id="20367569" target="_blank">20367569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27903528">
<a name="27903528"></a>Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i>. 2017;129(5):553-560. doi: 10.1182/blood-2016-01-689422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/27903528/pubmed" id="27903528" target="_blank">27903528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048 doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10643542">
<a name="10643542"></a>Ho AD, Suciu S, Stryckmans P, et al. Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group. <i>Ann Oncol</i>. 1999;10(12):1493-1498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/10643542/pubmed" id="10643542" target="_blank">10643542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17878478">
<a name="17878478"></a>Jacobsohn DA, Chen AR, Zahurak M, et al, “Phase II Study of Pentostatin in Patients With Corticosteroid-Refractory Chronic Graft-Versus-Host Disease,” <i>J Clin Oncol</i>, 2007, 25(27):4255-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/17878478/pubmed" id="17878478" target="_blank">17878478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19745067">
<a name="19745067"></a>Jacobsohn DA, Gilman AL, Rademaker A, et al. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. <i>Blood</i>. 2009;114(20):4354-4360.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/19745067/pubmed" id="19745067" target="_blank">19745067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17008537">
<a name="17008537"></a>Kay NE, Geyer SM, Call TG, et al. Combination Chemoimmunotherapy With Pentostatin, Cyclophosphamide, and Rituximab Shows Significant Clinical Activity With Low Accompanying Toxicity in Previously Untreated B Chronic Lymphocytic Leukemia. <i>Blood</i>. 2007;109(2):405-411.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/17008537/pubmed" id="17008537" target="_blank">17008537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE and Dorr RT, “Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,” <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16520464">
<a name="16520464"></a>Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia. <i>J Clin Oncol</i>. 2006;24(10):1575-1581.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/16520464/pubmed" id="16520464" target="_blank">16520464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12172976">
<a name="12172976"></a>Lathia C, Fleming GF, Meyer M, et al, “Pentostatin Pharmacokinetics and Dosing Recommendations in Patients With Mild Renal Impairment,” <i>Cancer Chemother Pharmacol</i>, 2002, 50(2):121-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/12172976/pubmed" id="12172976" target="_blank">12172976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10877045">
<a name="10877045"></a>Margolis J and Grever MR, "Pentostatin (Nipent): A Review of Potential Toxicity and Its Management," <i>Semin Oncol</i>, 2000, 27(2 Suppl 5):9-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/10877045/pubmed" id="10877045" target="_blank">10877045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7989933">
<a name="7989933"></a>Mercieca J, Matutes E, Dearden C, et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. <i>J Clin Oncol</i>. 1994;12(12):2588-2593.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/7989933/pubmed" id="7989933" target="_blank">7989933</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nipent (pentostatin) [prescribing information]. Lake Forest, IL: Hospira Inc; May 2018.</div>
</li>
<li>
<div class="reference">
                  Nipent (pentostatin) [prescribing information]. Lake Forest, IL: Hospira Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16795070">
<a name="16795070"></a>Osuji N, Matutes E, Tjonnfjord G, et al. T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature [published correction appears in <i>Cancer</i>. 2006;107(11):2744.]. <i>Cancer</i>. 2006;107(3):570-578. doi: 10.1002/cncr.22032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/16795070/pubmed" id="16795070" target="_blank">16795070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23588536">
<a name="23588536"></a>Poi MJ, Hofmeister CC, Johnston JS, et al. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. <i>Clin Pharmacokinet</i>. 2013;52(8):705-712.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/23588536/pubmed" id="23588536" target="_blank">23588536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19805674">
<a name="19805674"></a>Ravandi F, Aribi A, O’Brien S, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. <i>J Clin Oncol</i>. 2009;27(32):5425-5430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/19805674/pubmed" id="19805674" target="_blank">19805674</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20685255">
<a name="20685255"></a>Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. <i>Biol Blood Marrow Transplant</i>. 2011;17(1):1-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentostatin-drug-information/abstract-text/20685255/pubmed" id="20685255" target="_blank">20685255</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9756 Version 275.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
